Maintenance treatment for FRalpha-positive ovarian or endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the consent form and plan to follow all study visits and procedures
- You are a woman age 18 or older, with good overall health status (ECOG 0 or 1)
- You have high-grade serous or endometrioid ovarian cancer (or primary peritoneal or fallopian tube cancer), not certain other tumor types
- Your cancer responded or stayed stable after your most recent platinum chemotherapy (not progressed through it)
- Your tumor must test positive for FRalpha (high or medium expression) using available tissue samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
This trial tests a combination of two targeted drugs, cirtuvivint and olaparib, for a specific type of ovarian cancer that no longer responds to platinum chemotherapy. It may be an option if you have a BRCA mutation or HRD-positive tumor and have already tried a PARP inhibitor.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This study tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian cancer that has a specific protein (FRα). It's real-world research to see how well the drug works and how it affects people's daily lives.
Hear when a new Ovary Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.